胶质母细胞瘤中小胶质细胞免疫疗法的前景
本文综述了胶质母细胞瘤(GBM)免疫微环境中肿瘤相关巨噬细胞(尤其M2表型)的促瘤作用,并汇总了靶向PD-L1、CTLA-4、CSF-1R及疫苗、溶瘤病毒、抗体和CAR-T等免疫治疗临床试验的现状,指出利用免疫系统辅助治疗GBM仍处于早期探索阶段。
要点
- 肿瘤相关巨噬细胞(尤其M2表型)通过旁分泌和直接信号促进GBM生长。
- 靶向PD-L1、CTLA-4和CSF-1R的临床试验正在GBM中开展。
- 疫苗、溶瘤病毒、抗体和CAR-T等I/II期试验正在评估中。
核心结论
- 将免疫系统作为GBM治疗伙伴仍处于早期研究阶段,此类方法作为辅助治疗对攻克高度异质性GBM不可或缺。
研究设计与样本
- 综述性文章,讨论免疫系统如何形成有利微环境及针对免疫通路正在进行的临床试验。
主要发现
- 肿瘤相关巨噬细胞尤其M2表型是肿瘤微环境重要组分,通过旁分泌和直接信号促进肿瘤生长。
- 针对PD-L1、CTLA-4和集落刺激因子-1受体的临床试验正在GBM中研究。
- 多项I/II期临床试验正在使用疫苗、溶瘤病毒、抗体和靶向胶质瘤细胞的嵌合抗原受体T细胞。
临床怎么用
- 关注靶向PD-L1、CTLA-4、CSF-1R及细胞疗法等免疫治疗途径在GBM中的临床试验进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma (GBM) is the most aggressive primary tumor of the central nervous system. Despite aggressive multimodal therapy, it has a dismal prognosis. Over the last 20 years, the approach to GBM research and therapy has involved viewing the pathologic condition as a complex organ system with multiple nonneoplastic cells supporting tumor growth directly or through enhancement of the tumor microenvironment. Understanding the immune system effects on glioma growth, invasion, tumor survival, immune suppression, and angiogenesis is critical in immunotherapy target development. In this review, we discuss how the immune system generates a favorable microenvironment, and clinical trials currently underway targeting immune system pathways. Tumor-associated macrophages, particularly the M2 phenotype, are important residents of the tumor microenvironment, promoting tumor growth through paracrine and direct signaling. Clinical trials targeting PD-L-1, CTLA-4, and colony stimulating factor-1 receptor in GBM are currently under investigation. Additionally, several phase I/II clinical trials are underway using vaccines, oncolytic viruses, antibodies, and chimeric antigen receptor T cells targeting glioma cells. Co-opting the immune system as a therapeutic partner against GBM is in early stages of investigation, and the potential use of such approaches as treatment adjuncts is indispensable for combating this highly heterogeneous disease.
引用
- Rivera M, Bander ED, Cisse B, et al. Perspectives on Microglia-Based Immune Therapies Against Glioblastoma. World Neurosurg. 2021. PMID: 34583500. doi:10.1016/j.wneu.2021.06.127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。